PriceTargets.com logo

Biodexa Pharmaceuticals - BDRX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.00
  • Forecasted Upside: 572.27%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.19 As of 05/17/2024 01:00 AM ET
▼ -0.05 (-4.03%)

This chart shows the closing price for BDRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Biodexa Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BDRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BDRX

Analyst Price Target is $8.00
▲ +572.27% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Biodexa Pharmaceuticals in the last 3 months. The average price target is $8.00, with a high forecast of $8.00 and a low forecast of $8.00. The average price target represents a 572.27% upside from the last price of $1.19.

This chart shows the closing price for BDRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Biodexa Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/8/2024LADENBURG THALM/SH SHInitiated CoverageBuy$8.00Low
(Data available from 5/19/2019 forward)

News Sentiment Rating

0.77 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/19/2024

Current Sentiment

  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Biodexa Pharmaceuticals logo
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. In addition, the company offers licensing for MTD 201 (Q-octreotide) and MTD211 (Q-brexpiprazole). The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Read More

Today's Range

Now: $1.19
Low: $1.16
High: $1.37

50 Day Range

MA: $1.08
Low: $0.72
High: $1.62

52 Week Range

Now: $1.19
Low: $0.67
High: $20.39

Volume

487,464 shs

Average Volume

3,998,724 shs

Market Capitalization

$1.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.53

Frequently Asked Questions

What sell-side analysts currently cover shares of Biodexa Pharmaceuticals?

The following Wall Street analysts have issued reports on Biodexa Pharmaceuticals in the last year: LADENBURG THALM/SH SH.
View the latest analyst ratings for BDRX.

What is the current price target for Biodexa Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for Biodexa Pharmaceuticals in the last year. Their average twelve-month price target is $8.00, suggesting a possible upside of 572.3%. LADENBURG THALM/SH SH has the highest price target set, predicting BDRX will reach $8.00 in the next twelve months. LADENBURG THALM/SH SH has the lowest price target set, forecasting a price of $8.00 for Biodexa Pharmaceuticals in the next year.
View the latest price targets for BDRX.

What is the current consensus analyst rating for Biodexa Pharmaceuticals?

Biodexa Pharmaceuticals currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BDRX will outperform the market and that investors should add to their positions of Biodexa Pharmaceuticals.
View the latest ratings for BDRX.

What other companies compete with Biodexa Pharmaceuticals?

Other companies that are similar to Biodexa Pharmaceuticals include NeuBase Therapeutics, Ayala Pharmaceuticals, Panbela Therapeutics, GRI Bio and PaxMedica. Learn More about companies similar to Biodexa Pharmaceuticals.

How do I contact Biodexa Pharmaceuticals' investor relations team?

Biodexa Pharmaceuticals' physical mailing address is 1 CASPIAN POINT CASPIAN WAY, CARDIFF X0, CF10 4DQ. The company's listed phone number is 441235888300 and its investor relations email address is [email protected]. The official website for Biodexa Pharmaceuticals is www.midatechpharma.com. Learn More about contacing Biodexa Pharmaceuticals investor relations.